HeartBeam Inc. (NASDAQ: BEAT) is advancing cardiac care with a cable-free system that synthesizes a 12-lead electrocardiogram (ECG) from 3D, non-coplanar electrical signals captured in real time. This technology allows patients to record an ECG in 30 seconds at home or elsewhere when symptoms occur, reducing care delays for those experiencing cardiac issues. The HeartBeam System has FDA clearance for arrhythmia assessment, with its 12-lead ECG synthesis software under FDA review for the same indication. A partnership with AccurKardia integrates an FDA-cleared automated rhythm interpretation software, enhancing the arrhythmia solution. The company holds 20 issued patents with more pending, protecting its proprietary hardware, software, and algorithms.
HeartBeam is nearing commercial launch, targeting a $500 million concierge serviceable available market and a broader multibillion-dollar patient pay market, supported by a high-margin, recurring revenue model. This approach underscores the commercial viability of the innovation. The system aims to redefine cardiac care by enabling early detection and proactive monitoring outside traditional settings, with accuracy comparable to conventional 12-lead ECGs for arrhythmia detection but without wires, complex setup, or clinical staff. This makes synthesized 12-lead ECG signals accessible beyond medical facilities, empowering patients in managing their cardiac health. The technology offers a new paradigm prioritizing patient convenience, early detection, and timely intervention, potentially saving lives and reducing healthcare burdens globally.
